ES2062031T3 - Derivados de acido carboxilico. - Google Patents

Derivados de acido carboxilico.

Info

Publication number
ES2062031T3
ES2062031T3 ES89310994T ES89310994T ES2062031T3 ES 2062031 T3 ES2062031 T3 ES 2062031T3 ES 89310994 T ES89310994 T ES 89310994T ES 89310994 T ES89310994 T ES 89310994T ES 2062031 T3 ES2062031 T3 ES 2062031T3
Authority
ES
Spain
Prior art keywords
salts
basic
examples
carboxylic acid
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89310994T
Other languages
English (en)
Inventor
John Watson Clitherow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888825058A external-priority patent/GB8825058D0/en
Priority claimed from GB898914631A external-priority patent/GB8914631D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2062031T3 publication Critical patent/ES2062031T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

EL INVENTO SE REFIERE A SALES FORMADAS ENTRE ANTAGONISTAS RECEPTORES DE H2BASICOS Y UN COMPLEJO DE BISMUTO CON UN ACIDO CARBOXILICO, Y EL SOLVENTE DE TALES SALES, EXCLUYENDO LAS SALES EN LAS CUALES EL ANTAGONISTA DEL RECEPTOR H2- BASICO SEA RANITIDINA. EJEMPLOS DE ACIDOS CARBOXILICOS ADECUADOS SON EL ACIDO CITRICO Y EL ACIDO TARTARICO. EJEMPLOS DE LOS ANTAGONISTAS DEL RECEPTOR H2- BASICO SON LA CIMETIDINA, LA SULFOTIDINA, LA FAMOTIDINA Y LA NIZATIDINA. LAS SALES SON UTILES EN EL TRATAMIENTO DE DESORDENES GASTROINTESTINALES, PARTICULARMENTE EN CONDICIONES GASTRODUODENALES. LAS SALES PRESENTAN UNA ACTIVIDAD ANTISECRECTORA ASOCIADA CON EL ANTAGONISTA DEL RECEPTOR H2 - BASICO JUNTO CON LA ACTIVIDAD ANTIBACTERIANA CONTRA "CAMPYLOBACTER PYLORI" Y TAMBIEN POSEEN PROPIEDADES CITOPROTECTORAS.
ES89310994T 1988-10-26 1989-10-25 Derivados de acido carboxilico. Expired - Lifetime ES2062031T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888825058A GB8825058D0 (en) 1988-10-26 1988-10-26 Chemical compounds
GB898914631A GB8914631D0 (en) 1989-06-26 1989-06-26 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2062031T3 true ES2062031T3 (es) 1994-12-16

Family

ID=26294554

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89310994T Expired - Lifetime ES2062031T3 (es) 1988-10-26 1989-10-25 Derivados de acido carboxilico.

Country Status (8)

Country Link
US (1) US5273984A (es)
EP (1) EP0367484B1 (es)
JP (1) JP2915021B2 (es)
KR (1) KR0148480B1 (es)
AU (1) AU641903B2 (es)
CA (1) CA2001436C (es)
DE (1) DE68913137T2 (es)
ES (1) ES2062031T3 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009437D0 (en) * 1990-04-26 1990-06-20 Glaxo Group Ltd Chemical compounds
DE69117955T2 (de) * 1990-07-20 1996-09-19 Tillotts Pharma Ag, Ziefen Produkte und verfahren zur behandlung des verdauungskanals
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
CA2052698A1 (en) * 1990-10-11 1992-04-12 Roger G. Berlin Treatment of peptic ulcer
BG61302B1 (bg) * 1993-09-30 1997-05-30 Нихфи Ад n-(3-(3-(1-пиперидинилметил)фенокси)пропил)хидроксиацетамид 1,2,3-пропентрикарбоксилат бисмут /3+/комплекс и метод за получаването му
US6902738B2 (en) 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US5834002A (en) * 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
GB9501560D0 (en) * 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
JPH10512877A (ja) * 1995-01-26 1998-12-08 ニコムド イメージング エイ／エス ビスマス化合物
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
CN1102585C (zh) * 1999-04-28 2003-03-05 常州兰陵制药有限公司 雷尼替丁枸橼酸铋盐的制备方法
US20030158118A1 (en) * 2001-11-26 2003-08-21 Weidner Morten Sloth Combination of cimetidine and cysteine derivatives for treating cancer
US20050031706A1 (en) * 2003-08-06 2005-02-10 Pena Lorraine E. Viscosity-stable compositions useful for treating gastrointestinal disorders
CN111592503B (zh) * 2020-06-02 2021-07-16 青岛市食品药品检验研究院（青岛市药品不良反应监测中心、青岛市实验动物和动物实验中心） 一种法莫替丁与苹果酸的共晶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3686836T2 (de) * 1985-06-13 1993-03-04 Marshall Barry James Zusammensetzungen zur behandlung von magen-darmstoerungen.
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
CH679582A5 (es) * 1988-07-18 1992-03-13 Glaxo Group Ltd

Also Published As

Publication number Publication date
JPH02256623A (ja) 1990-10-17
KR900005975A (ko) 1990-05-07
DE68913137D1 (de) 1994-03-24
AU4364789A (en) 1990-05-03
CA2001436A1 (en) 1990-04-26
JP2915021B2 (ja) 1999-07-05
EP0367484B1 (en) 1994-02-16
EP0367484A1 (en) 1990-05-09
DE68913137T2 (de) 1994-05-26
US5273984A (en) 1993-12-28
AU641903B2 (en) 1993-10-07
KR0148480B1 (ko) 1998-11-02
CA2001436C (en) 2000-01-25

Similar Documents

Publication Publication Date Title
ES2062031T3 (es) Derivados de acido carboxilico.
ES2014175A6 (es) Procedimiento de preparacion de sales de un derivado furanico.
EP0228893A3 (en) Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl group in allergy treatment
FI883807A7 (fi) Menetelmä farmakologisesti aktiivisten 7-(3-substituoitu-1-pyrrolidinyyli)-1-syklopropyyli-1,4-dihydro-4-okso-1,8-naftyridiini-3-karboksyylihappojohdannaisten valmistamiseksi
FI872864L (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
NO860332L (no) Fremgangsmaate for fremstilling av terapeutisk aktive alfa-(2-okso-2,4,5,6,7,7a-heksahydro-tieno(3,2-c)-5-pyridyl)-fenyl-eddiksyre-derivater.
ES2038074A1 (es) Nuevos derivados de benzimidazol, su preparacion y su aplicacion como medicamentos.
DE69005290D1 (de) Mähdrescher-Elevator zum Anschliessen der Mähwerksplattform an der Basis-Einheit.
IT1079705B (it) Procedimento per la produzione del cloridrato di 2,6-xilidide dell'acido n-metilpiperidin-2-carbossilico
RU93047023A (ru) Производные имидазола-антагонисты ангиотензина-11, их получение и терапевтическое применение
SE8400445D0 (sv) Novel pharmaceutical active 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)quinoline derivatives, their production and use
DK45385D0 (da) Hexahydroarylquinolizin og farmaceutisk praeparat indeholdende en saadanforbindelse
ES2083374T3 (es) Derivados amidicos en posicion c63 de 34-des(acetilglucosaminil)-34-desoxi-teicoplaninas.
IT8222712A0 (it) Foraggi e mangimi e additivi per foraggi e mangimi, atti a promuovere l'incremento di peso di animali di allevamento, eprocedimento per la loro produzione.
GB1187348A (en) New Amidoximes and process for the preparation thereof
DK447387A (da) Hexahydroarylquinolizinforbindelse og farmaceutisk praeparat indeholdende en saadan forbindelse
JPS5735358A (en) Lead frame and semiconductor device using said frame
ES8307409A1 (es) "una maquina cableadora para el cableado simetrico de al menos dos alambres".
GB1447827A (en) Benzimidazole derivatives
IT1220590B (it) Macchina semiautomatica per le operazioni di raccolta,mondatura e stipatura delle drupe dell'olivo e di alstri frutti simili
IT8025840A0 (it) Macchina per la raccolta di frutta e piu' particolarmente per la vendemmia dell'uva.
IT8882206A0 (it) Prodotto per lo scioglimento del cerume interno dell'orecchio umano.
ES554639A0 (es) Mejoras indtroducidas en el objeto de la patente principal n. 543908 por: procedimiento de soldadura por ultrasonidos de tejido de poliamida.
IT994795B (it) Macchina per la raccolta e la mondatura di nocciole e simili frutti
RU93045020A (ru) Энантиомеры ароматических азотсодержащих производных и способ их получения

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 367484

Country of ref document: ES